Liang Zhenlin, Liu Lijuan, Zhou Yanyu, Liu Wukun, Lu Yunlong
Jiangsu Collaborative Innovation Center of Chinese Medicinal Resources Industrialization, School of Medicine & Holistic Integrative Medicine, Nanjing University of Chinese Medicine, Nanjing, 210023, P. R. China.
State key Laboratory of Coordination Chemistry, Nanjing University, Nanjing, 210023, P. R. China.
J Med Chem. 2023 Feb 23;66(4):2235-2256. doi: 10.1021/acs.jmedchem.2c01458. Epub 2023 Feb 13.
Breast cancer is the most prevalent cancer in women and represents a serious disease that is harmful to life and health. In 1977, with the approval of tamoxifen, endocrine therapy has become the main clinical treatment for ER-positive (ER+) breast cancer. Although patients initially respond well to endocrine therapies, drug resistance often emerges and side effects can be challenging. To overcome drug resistance, the exploration for new drugs is a priority. Metal complexes have demonstrated significant antitumor activities, and platinum complexes are widely used in the clinic against various cancers, including breast cancer. In this Perspective, the first section describes the classification and mechanism of endocrine therapy drugs for ER+ breast cancer, and the second section summarizes research since 2000 into metal complexes with activity toward ER+ breast cancer. Finally, we discuss the opportunities, challenges, and future directions for metal complexes in the treatment of ER+ breast cancer.
乳腺癌是女性中最常见的癌症，是一种严重危害生命健康的疾病。1977年，随着他莫昔芬获批，内分泌治疗成为雌激素受体阳性（ER+）乳腺癌的主要临床治疗方法。尽管患者最初对内分泌治疗反应良好，但耐药性往往会出现，且副作用也颇具挑战性。为克服耐药性，探索新药是当务之急。金属配合物已显示出显著的抗肿瘤活性，铂配合物在临床上被广泛用于治疗包括乳腺癌在内的各种癌症。在本综述中，第一部分描述了ER+乳腺癌内分泌治疗药物的分类和作用机制，第二部分总结了自2000年以来对具有抗ER+乳腺癌活性的金属配合物的研究。最后，我们讨论了金属配合物在治疗ER+乳腺癌方面的机遇、挑战和未来方向。
